International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 082-088
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Effect of Haematological Parameters on Overall Survival in Advanced Stage Non Small Cell Lung Cancer
Arzu OGUZ1, Dilsen COLAK2, Ugur ERSOY2, Inanc G. IMAMOGLU2, Mustafa ALTINBAS2, Dilek UNAL3, Gokmen ZARARSIZ4
1Baskent University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Diskapi Yildirim Beyazit Training and Research Hospital, Medical Oncology Clinic, Ankara, TURKEY
3Kayseri Training and Research Hospital, Department of Radiation Oncology Clinic, Kayseri, TURKEY
4Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, TURKEY
Keywords: Anemia,Leukocytosis, Non Small cell lung cancer, Survival, Thrombocytosis
In this study, we aimed to evaluate the prognostic value of pretreatment blood count values, particularly WBC counts, in patients with advanced non-small cell lung cancer (NSCLC). The records of 186 patients with advanced stage (stage IIIB and IV) NSCLC were assessed retrospectively. Patients were divided into 3 subgroups according to WBC levels; ≤10000 /mm3 as Group 1, >10000 and ≤15000/mm3 as Group 2 and >15000/mm3 as Group 3. Patient and tumor characteristics as well as outcomes in terms of overall survival (OS) were evaluated. Median OS was 13.3 months in the whole population, 25.7 months in stage IIIB and 8.9 months in stage IV patients. According to the pretreatment leukocyte values, median OS was 17.9 months in Group 1, 11.2 months in Group 2 and 8.4 months in Group 3 (p= 0.003). Median OS values in WBC groups according to stages IIIB and IV were significantly different (p< 0.001). In multivariate analyses, ECOG-PS 2 or 3, stage IV disease, anemia and high WBC levels were associated with poorer OS. In this study, higher pretreatment WBC levels were associated with poorer OS in patients with advanced stage NSCLC. Pretreatment WBC counts may represent a simple prognostic factor and may aid in tailoring treatment in patients with advanced NSCLC.
Arzu OGUZ1, Dilsen COLAK2, Ugur ERSOY2, Inanc G. IMAMOGLU2, Mustafa ALTINBAS2, Dilek UNAL3, Gokmen ZARARSIZ4
1Baskent University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Diskapi Yildirim Beyazit Training and Research Hospital, Medical Oncology Clinic, Ankara, TURKEY
3Kayseri Training and Research Hospital, Department of Radiation Oncology Clinic, Kayseri, TURKEY
4Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, TURKEY
Keywords: Anemia,Leukocytosis, Non Small cell lung cancer, Survival, Thrombocytosis
In this study, we aimed to evaluate the prognostic value of pretreatment blood count values, particularly WBC counts, in patients with advanced non-small cell lung cancer (NSCLC). The records of 186 patients with advanced stage (stage IIIB and IV) NSCLC were assessed retrospectively. Patients were divided into 3 subgroups according to WBC levels; ≤10000 /mm3 as Group 1, >10000 and ≤15000/mm3 as Group 2 and >15000/mm3 as Group 3. Patient and tumor characteristics as well as outcomes in terms of overall survival (OS) were evaluated. Median OS was 13.3 months in the whole population, 25.7 months in stage IIIB and 8.9 months in stage IV patients. According to the pretreatment leukocyte values, median OS was 17.9 months in Group 1, 11.2 months in Group 2 and 8.4 months in Group 3 (p= 0.003). Median OS values in WBC groups according to stages IIIB and IV were significantly different (p< 0.001). In multivariate analyses, ECOG-PS 2 or 3, stage IV disease, anemia and high WBC levels were associated with poorer OS. In this study, higher pretreatment WBC levels were associated with poorer OS in patients with advanced stage NSCLC. Pretreatment WBC counts may represent a simple prognostic factor and may aid in tailoring treatment in patients with advanced NSCLC.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |